Bionano Genomics Posts Modest Revenue Growth Amid Rising OGM Adoption
Event summary
- Bionano Genomics reported $6.7M in Q1 2026 revenue, up 4% YoY, with consumables revenue rising 20% to $3.9M.
- Sold 8,178 nanochannel array flow cells, a 17% increase from Q1 2025.
- Gross margin improved to 49% from 46% in Q1 2025.
- New CPT code (81354) for OGM in cytogenomic analysis went effective January 1, 2026.
- 2026 revenue guidance set at $30–33M, with Q2 expected at $7.5–7.8M.
The big picture
Bionano Genomics is positioning itself as a key player in the genomic analysis space, with OGM gaining traction in both research and clinical applications. The company's focus on expanding its evidence base and improving financial metrics comes amid broader industry trends toward personalized medicine and advanced diagnostic tools. The strategic milestone of retiring secured convertible debt could further strengthen its financial position, allowing for greater investment in growth initiatives.
What we're watching
- Market Adoption
- How the expansion of OGM applications across hematologic malignancies, constitutional genetics, and cell and gene therapy will drive further revenue growth.
- Financial Health
- Whether Bionano can sustain its gross margin improvements and manage operating expenses to reach profitability.
- Regulatory Impact
- The pace at which new CPT codes and increased reimbursement rates will accelerate OGM adoption in clinical settings.
Related topics